How much funding has Aplagon raised?

Aplagon has raised $9.9M in total funding, most recently a Venture Round.

Where is Aplagon headquartered?

Aplagon is headquartered in Helsinki.

Aplagon

Q: Who are Aplagon's investors?

Aplagon's investors include Fåhraeus Startup and Growth, European Innovation Council Fund, Innovestor.

Pioneering first-in-class treatments for thromboinflammatory diseases

Helsinki · Founded 2009 · $9.9M raised

Biotech

Headquarters: Helsinki
Founded: 2009
Business Model: B2B
Website: aplagon.com

Total Funding: $9.9M
Last Round: $7.3M Venture RoundFeb 2025
Rounds: 2

About

Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for thromboinflammatory diseases. It is based on pioneering research on mast cell-derived heparin proteoglycans (HEP-PG) by Prof. Riitta Lassila's group at the Wihuri Research Institute in Helsinki, Finland, which led to Aplagon's lead candidate APAC — a heparin proteoglycan mimetic now in clinical studies across two lead cardiovascular indications. Aplagon's offices and laboratory are at Biomedicum Helsinki, a prominent life-science hub in Finland.

Summary

Aplagon is a Biotech company based in Helsinki, founded in 2009. It has raised $9.9M in total across 2 rounds, most recently a $7.3M Venture Round round in Feb 2025. Investors include Fåhraeus Startup and Growth, European Innovation Council Fund and Innovestor.